WO2015092393A3 - Ligands specifically binding to human targets of interest - Google Patents

Ligands specifically binding to human targets of interest Download PDF

Info

Publication number
WO2015092393A3
WO2015092393A3 PCT/GB2014/053729 GB2014053729W WO2015092393A3 WO 2015092393 A3 WO2015092393 A3 WO 2015092393A3 GB 2014053729 W GB2014053729 W GB 2014053729W WO 2015092393 A3 WO2015092393 A3 WO 2015092393A3
Authority
WO
WIPO (PCT)
Prior art keywords
interest
specifically binding
human targets
ligands specifically
ligands
Prior art date
Application number
PCT/GB2014/053729
Other languages
French (fr)
Other versions
WO2015092393A2 (en
Inventor
Jasper Clube
Original Assignee
Kymab Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1322253.4A external-priority patent/GB2521356B/en
Priority claimed from GB1322250.0A external-priority patent/GB2521355A/en
Priority claimed from US14/138,446 external-priority patent/US8883157B1/en
Priority claimed from EP14172579.6A external-priority patent/EP2886558A1/en
Priority claimed from US14/331,665 external-priority patent/US9023359B1/en
Priority claimed from US14/331,609 external-priority patent/US9051378B1/en
Priority claimed from US14/331,730 external-priority patent/US9914769B2/en
Priority claimed from US14/457,536 external-priority patent/US9017678B1/en
Priority claimed from US14/457,566 external-priority patent/US8945560B1/en
Priority claimed from US14/472,685 external-priority patent/US8992927B1/en
Priority claimed from US14/472,698 external-priority patent/US8986694B1/en
Priority claimed from US14/472,828 external-priority patent/US8986691B1/en
Priority claimed from US14/472,818 external-priority patent/US8980273B1/en
Priority claimed from EP14185297.0A external-priority patent/EP2975058A1/en
Priority claimed from US14/500,233 external-priority patent/US9045548B1/en
Priority claimed from US14/507,368 external-priority patent/US9034332B1/en
Priority claimed from US14/536,049 external-priority patent/US9045545B1/en
Priority claimed from US14/537,403 external-priority patent/US9067998B1/en
Priority to JP2016541434A priority Critical patent/JP6720079B2/en
Application filed by Kymab Limited filed Critical Kymab Limited
Priority to CN201480075772.XA priority patent/CN106062004A/en
Priority to DE112014005975.7T priority patent/DE112014005975T5/en
Priority to EP23207654.7A priority patent/EP4328245A3/en
Priority to EP14199053.1A priority patent/EP2975059A1/en
Priority to EP17199373.6A priority patent/EP3332790A1/en
Priority to IES20140321A priority patent/IES86623B2/en
Publication of WO2015092393A2 publication Critical patent/WO2015092393A2/en
Priority to DE202015008974.7U priority patent/DE202015008974U1/en
Priority to PCT/EP2015/066099 priority patent/WO2016008899A1/en
Priority to DE202015008988.7U priority patent/DE202015008988U1/en
Priority to PCT/EP2015/068491 priority patent/WO2016023916A1/en
Publication of WO2015092393A3 publication Critical patent/WO2015092393A3/en
Priority to PCT/GB2015/053361 priority patent/WO2016071701A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Physical Vapour Deposition (AREA)

Abstract

The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
PCT/GB2014/053729 2013-12-17 2014-12-17 Human targets WO2015092393A2 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN201480075772.XA CN106062004A (en) 2013-12-17 2014-12-17 Ligands specifically binding to human targets of interest
JP2016541434A JP6720079B2 (en) 2013-12-17 2014-12-17 A ligand that specifically binds to a human target of interest
DE112014005975.7T DE112014005975T5 (en) 2013-12-17 2014-12-17 Human goals
EP23207654.7A EP4328245A3 (en) 2014-07-15 2014-12-18 Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP14199053.1A EP2975059A1 (en) 2014-07-15 2014-12-18 Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
EP17199373.6A EP3332790A1 (en) 2014-07-15 2014-12-18 Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations
IES20140321A IES86623B2 (en) 2014-07-15 2014-12-22 An injectable antibody preparation for use in reducing or maintaining previously reduced cholesterol level
PCT/EP2015/066099 WO2016008899A1 (en) 2014-07-15 2015-07-15 Targeting human pcsk9 for cholesterol treatment
DE202015008988.7U DE202015008988U1 (en) 2014-07-15 2015-07-15 Targeting of human PCSK9 for cholesterol treatment
DE202015008974.7U DE202015008974U1 (en) 2014-07-15 2015-07-15 Targeting of human PCSK9 for cholesterol treatment
PCT/EP2015/068491 WO2016023916A1 (en) 2014-08-12 2015-08-11 Treatment of disease using ligand binding to targets of interest
PCT/GB2015/053361 WO2016071701A1 (en) 2014-11-07 2015-11-06 Treatment of disease using ligand binding to targets of interest

Applications Claiming Priority (66)

Application Number Priority Date Filing Date Title
US201361916866P 2013-12-17 2013-12-17
US201361916862P 2013-12-17 2013-12-17
US61/916,862 2013-12-17
GB1322253.4 2013-12-17
GB1322253.4A GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods
GB1322250.0A GB2521355A (en) 2013-12-17 2013-12-17 Human targets I
GB1322250.0 2013-12-17
US61/916,866 2013-12-17
US14/138,446 2013-12-23
US14/138,446 US8883157B1 (en) 2013-12-17 2013-12-23 Targeting rare human PCSK9 variants for cholesterol treatment
US14/228,760 2014-03-28
US14/228,760 US8951523B1 (en) 2013-12-17 2014-03-28 Targeting rare human PCSK9 variants for cholesterol treatment
EP14172579.6A EP2886558A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
EP14172579.6 2014-06-16
EP14172578.8 2014-06-16
EP14172578.8A EP2886557A1 (en) 2013-12-17 2014-06-16 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US14/331,665 2014-07-15
US14/331,730 US9914769B2 (en) 2014-07-15 2014-07-15 Precision medicine for cholesterol treatment
US14/331,609 US9051378B1 (en) 2014-07-15 2014-07-15 Targeting rare human PCSK9 variants for cholesterol treatment
US14/331,609 2014-07-15
US14/331,730 2014-07-15
US14/331,665 US9023359B1 (en) 2014-07-15 2014-07-15 Targeting rare human PCSK9 variants for cholesterol treatment
US14/457,536 2014-08-12
US14/457,566 2014-08-12
US14/457,566 US8945560B1 (en) 2014-07-15 2014-08-12 Method of treating rheumatoid arthritis using antibody to IL6R
US14/457,536 US9017678B1 (en) 2014-07-15 2014-08-12 Method of treating rheumatoid arthritis using antibody to IL6R
US14/472,698 2014-08-29
US14/472,685 US8992927B1 (en) 2014-07-15 2014-08-29 Targeting human NAV1.7 variants for treatment of pain
US14/472,818 US8980273B1 (en) 2014-07-15 2014-08-29 Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/472,685 2014-08-29
US14/472,818 2014-08-29
US14/472,828 US8986691B1 (en) 2014-07-15 2014-08-29 Method of treating atopic dermatitis or asthma using antibody to IL4RA
US14/472,828 2014-08-29
US14/472,698 US8986694B1 (en) 2014-07-15 2014-08-29 Targeting human nav1.7 variants for treatment of pain
EP14185297.0A EP2975058A1 (en) 2014-07-15 2014-09-18 Antibodies for use in treating conditions related to specific PCSK9 variants in specific patient populations
US14/490,175 US9040052B1 (en) 2013-12-17 2014-09-18 Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US14/490,091 US9068012B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,091 2014-09-18
US14/490,160 US8999341B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
US14/490,160 2014-09-18
US14/490,175 2014-09-18
US14/490,112 2014-09-18
US14/490,112 US9034331B1 (en) 2014-07-15 2014-09-18 Targeting rare human PCSK9 variants for cholesterol treatment
EP14185297.0 2014-09-18
US14/500,233 2014-09-29
US14/500,233 US9045548B1 (en) 2014-07-15 2014-09-29 Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US14/500,397 US10618971B2 (en) 2013-12-17 2014-09-29 Targeting rare human PCSK9 variants for cholesterol treatment
US14/500,397 2014-09-29
US14/507,368 2014-10-06
US14/507,368 US9034332B1 (en) 2014-07-15 2014-10-06 Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
EP14190945 2014-10-29
EP14190945.7 2014-10-29
US14/536,129 2014-11-07
US14/536,049 2014-11-07
US14/536,129 US9062105B1 (en) 2014-07-15 2014-11-07 Precision Medicine by targeting VEGF-A variants for treatment of retinopathy
US14/536,049 US9045545B1 (en) 2014-07-15 2014-11-07 Precision medicine by targeting PD-L1 variants for treatment of cancer
US14/537,403 US9067998B1 (en) 2014-07-15 2014-11-10 Targeting PD-1 variants for treatment of cancer
US14/537,403 2014-11-10
US14/552,816 US10611849B2 (en) 2013-12-17 2014-11-25 Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US14/552,816 2014-11-25
EP14196638 2014-12-05
EP14196641 2014-12-05
EP14196645.7 2014-12-05
EP14196638.2 2014-12-05
EP14196641.6 2014-12-05
EP14196645 2014-12-05

Publications (2)

Publication Number Publication Date
WO2015092393A2 WO2015092393A2 (en) 2015-06-25
WO2015092393A3 true WO2015092393A3 (en) 2015-09-11

Family

ID=53402177

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/GB2014/053729 WO2015092393A2 (en) 2013-12-17 2014-12-17 Human targets
PCT/GB2014/053730 WO2015092394A1 (en) 2013-12-17 2014-12-17 Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/053730 WO2015092394A1 (en) 2013-12-17 2014-12-17 Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations

Country Status (1)

Country Link
WO (2) WO2015092393A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI686405B (en) 2008-12-09 2020-03-01 建南德克公司 Anti-pd-l1 antibodies and their use to enhance t-cell function
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
MX2017011644A (en) 2015-03-13 2017-12-04 Cytomx Therapeutics Inc Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof.
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
US10626165B2 (en) 2016-12-14 2020-04-21 Janssen Biotech, Inc. CD8a-binding fibronectin type III domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
US11168144B2 (en) 2017-06-01 2021-11-09 Cytomx Therapeutics, Inc. Activatable anti-PDL1 antibodies, and methods of use thereof
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2022551204A (en) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー CD71-binding fibronectin type III domain
CA3184082A1 (en) * 2020-07-02 2022-01-06 David Scott Johnson Anti-ctla-4 binding proteins and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092771A2 (en) * 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2006091899A2 (en) * 2005-02-24 2006-08-31 Amgen Inc. Epidermal growth factor receptor mutations
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2012154999A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders
WO2013041844A2 (en) * 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013169886A1 (en) * 2012-05-08 2013-11-14 Alderbio Holdings Llc Anti-pcsk9 antibodies and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092771A2 (en) * 2001-05-11 2002-11-21 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2006091899A2 (en) * 2005-02-24 2006-08-31 Amgen Inc. Epidermal growth factor receptor mutations
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2012154999A1 (en) * 2011-05-10 2012-11-15 Amgen Inc. Methods of treating or preventing cholesterol related disorders
WO2013041844A2 (en) * 2011-09-19 2013-03-28 Kymab Limited Antibodies, variable domains & chains tailored for human use
WO2013169886A1 (en) * 2012-05-08 2013-11-14 Alderbio Holdings Llc Anti-pcsk9 antibodies and use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JANICE MAYNE ET AL: "Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations", LIPIDS IN HEALTH AND DISEASE, BIOMED CENTRAL, LONDON, GB, vol. 12, no. 1, 10 May 2013 (2013-05-10), pages 70, XP021151113, ISSN: 1476-511X, DOI: 10.1186/1476-511X-12-70 *
RICHARD M. DURBIN ET AL: "A map of human genome variation from population-scale sequencing", NATURE, vol. 467, no. 7319, 28 October 2010 (2010-10-28), pages 1061 - 1073, XP055048531, ISSN: 0028-0836, DOI: 10.1038/nature09534 *

Also Published As

Publication number Publication date
WO2015092394A1 (en) 2015-06-25
WO2015092393A2 (en) 2015-06-25

Similar Documents

Publication Publication Date Title
WO2015092393A3 (en) Ligands specifically binding to human targets of interest
EP3532613A4 (en) Methods and compositions for rna mapping
EP3665156A4 (en) Compounds, compositions and methods
EP3397261A4 (en) Methods and compositions relating to chondrisomes
EP3676297A4 (en) Compounds, compositions and methods
EP3377657A4 (en) Transformable tagging compositions, methods, and processes incorporating same
WO2016079696A3 (en) Conductive polymer coatings for three dimensional substrates
WO2016011306A3 (en) Terminal modifications of polynucleotides
EP3600325A4 (en) Novel compositions and methods
WO2016073789A3 (en) Anti-fgfr2/3 antibodies and methods using same
EP3600271A4 (en) Methods and compositions for enhancing health
WO2014144600A3 (en) Multivalent and monovalent multispecific complexes and their uses
WO2016061389A3 (en) Anti-alpha-synuclein antibodies and methods of use
EP3316909A4 (en) Anti-ntb-a antibodies and related compositions and methods
WO2015066452A3 (en) Methods of treating pediatric cancers
WO2014152157A8 (en) Methods and compositions for the generation and use of conformation-specific antibodies
EP3140305A4 (en) Novel compositions, uses and methods for making them
EP3565596A4 (en) Methods and compositions relating to anti-chi3l1 antibody reagents
WO2016098079A3 (en) Compositions and methods for antibodies targeting bmp6
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
EP3588499A4 (en) Photopolymer composition
CN106659716A8 (en) Ah pyrrole not moral composition and its application method
EP3068500A4 (en) Fertilizer compositions and methods of making and using the same
EP3038602A4 (en) Edible coating compositions, edible coatings, and methods for making and using the same
EP3672636A4 (en) Methods and compositions relating to anti-chi3l1 antibody reagents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14815814

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2016541434

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 112014005975

Country of ref document: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14815814

Country of ref document: EP

Kind code of ref document: A2